Daiwa has issued a research report maintaining its "Buy" rating on LAIFUAL (03952) with a 12-month target price of HK$66, according to an app report.
The company has recently seen a continuous increase in inquiries from humanoid robot original equipment manufacturers (OEMs) in Japan, South Korea, and China's Taiwan region, and some cooperation projects are expected to reach clearer partnerships between the fourth quarter of this year and the first quarter of next year.
The bank noted that aside from Tesla and Figure AI, which explicitly require suppliers to have overseas production capacity, most overseas customers accept supply from Zhejiang LAIFUAL's domestic factories in China, and the company also maintains close contact with customers in Europe and North America.
Daiwa mentioned that LAIFUAL's partnership with Japanese company Harmonic Drive Systems (HDS) has already provided an additional channel for entering the Japanese market, with harmonic reducers jointly developed by the two parties already adopted by industrial robot manufacturers such as Yaskawa Electric. These products perform close to HDS's original standards but are priced at only one-third to one-half of HDS's offerings. Since HDS has disclosed LAIFUAL's participation in the project to its customers, the bank believes this will bring potential orders and international brand endorsement.
The report analyzed that the average selling price (ASP) of LAIFUAL's harmonic reducers has declined from approximately RMB 800 in 2023 to RMB 500 in the first half of 2026. Management emphasized that this decline is not due to competitive pressure but rather a shift in product mix, from larger products used in industrial robots to smaller products for humanoid and collaborative robots, which has lowered the overall average selling price. Meanwhile, unit costs also fell from RMB 560 in 2023 to RMB 350 in the first half of 2026, mainly benefiting from improved material formulations, internalization of production processes, and enhanced efficiency of key components, with processing time for some components reduced from 2 to 3 hours to less than 10 minutes. Overall, management expects to achieve a gross margin of 30% to 35% between 2027 and 2029.
The bank also believes that medical surgical robots present high-end development opportunities for the company. It is currently testing products with the da Vinci Surgical System, with each robot requiring approximately 60 harmonic reducers. Although no mass production orders have been confirmed yet, if certification is successfully obtained, it would not only significantly increase the component value per unit but also help strengthen market confidence in its precision and reliability.
Comments